AmerisourceBergen Corp. (ABC) Given Consensus Rating of “Buy” by Analysts
AmerisourceBergen Corp. (NYSE:ABC) has earned a consensus recommendation of “Buy” from the eighteen brokerages that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, seven have issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $93.20.
A number of analysts have commented on ABC shares. Jefferies Group set a $95.00 price target on shares of AmerisourceBergen and gave the company a “hold” rating in a research note on Tuesday, August 29th. ValuEngine cut shares of AmerisourceBergen from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. Needham & Company LLC reiterated a “buy” rating and issued a $91.00 price target on shares of AmerisourceBergen in a research note on Sunday, September 10th. Morgan Stanley cut shares of AmerisourceBergen from an “overweight” rating to an “equal weight” rating in a research note on Thursday, September 14th. Finally, Royal Bank of Canada started coverage on shares of AmerisourceBergen in a research note on Tuesday, September 19th. They issued a “sector perform” rating and a $87.00 price target for the company.
AmerisourceBergen (NYSE:ABC) traded up $0.79 during trading on Tuesday, reaching $93.25. 734,272 shares of the company were exchanged, compared to its average volume of 1,797,201. The company has a market capitalization of $20,163.86, a P/E ratio of 50.41, a P/E/G ratio of 1.60 and a beta of 1.00. AmerisourceBergen has a 1-year low of $71.90 and a 1-year high of $97.85. The company has a current ratio of 0.91, a quick ratio of 0.48 and a debt-to-equity ratio of 1.83.
The business also recently announced a quarterly dividend, which was paid on Monday, December 4th. Stockholders of record on Monday, November 20th were paid a dividend of $0.38 per share. This represents a $1.52 dividend on an annualized basis and a dividend yield of 1.63%. The ex-dividend date was Friday, November 17th. This is a boost from AmerisourceBergen’s previous quarterly dividend of $0.37. AmerisourceBergen’s dividend payout ratio (DPR) is currently 82.16%.
In other AmerisourceBergen news, insider Peyton R. Howell sold 17,800 shares of AmerisourceBergen stock in a transaction dated Thursday, December 14th. The shares were sold at an average price of $89.70, for a total value of $1,596,660.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Tim G. Guttman sold 11,600 shares of AmerisourceBergen stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $82.78, for a total transaction of $960,248.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 176,364 shares of company stock valued at $14,429,980. 27.40% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently modified their holdings of the business. Parallel Advisors LLC grew its holdings in shares of AmerisourceBergen by 3.2% during the 2nd quarter. Parallel Advisors LLC now owns 1,109 shares of the company’s stock valued at $104,000 after purchasing an additional 34 shares during the last quarter. Sun Life Financial INC grew its holdings in shares of AmerisourceBergen by 15,000.0% during the 2nd quarter. Sun Life Financial INC now owns 1,208 shares of the company’s stock valued at $114,000 after purchasing an additional 1,200 shares during the last quarter. D.A. Davidson & CO. grew its holdings in shares of AmerisourceBergen by 29.0% during the 2nd quarter. D.A. Davidson & CO. now owns 1,668 shares of the company’s stock valued at $157,000 after purchasing an additional 375 shares during the last quarter. Intl Fcstone Inc. bought a new stake in shares of AmerisourceBergen during the 2nd quarter valued at approximately $201,000. Finally, Pinnacle Associates Ltd. bought a new stake in shares of AmerisourceBergen during the 2nd quarter valued at approximately $203,000. Institutional investors and hedge funds own 67.83% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This article was first published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this article on another site, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this article can be viewed at https://theolympiareport.com/2017/12/26/amerisourcebergen-corp-abc-given-consensus-rating-of-buy-by-analysts.html.
AmerisourceBergen Company Profile
AmerisourceBergen Corporation is a pharmaceutical sourcing and distribution services company. The Company’s segments include Pharmaceutical Distribution and Other. The Company provides services to healthcare providers, and pharmaceutical and biotech manufacturers. As of June 30, 2016, the Pharmaceutical Distribution segment consists of two operating segments, including the operations of AmerisourceBergen Drug Corporation (ABDC) and AmerisourceBergen Specialty Group (ABSG), which distributes specialty drugs to their customers.
Receive News & Ratings for AmerisourceBergen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AmerisourceBergen and related companies with MarketBeat.com's FREE daily email newsletter.